Latest Biotech News

The FDA granted accelerated approval to Beqalzi (sonrotoclax), becoming the first BCL2 inhibitor approved specifically for relapsed or refractory mantle cell lymphoma after at least two prior...

Lilly’s Phase 1 base-editing results on VERVE-102 are paired with continued momentum in AI-enabled precision approaches for disease biology and clinical decision-making. Separate disclosures from...

Researchers published results supporting continuous fetal monitoring using a wearable ultrasound patch designed to reduce dependence on highly trained sonographers. The work—led by a team...

Lilly’s gene-editing LDL story is part of a broader cardiovascular prevention push that is increasingly shaped by genetics-driven mechanisms and one-time dosing concepts. In parallel, early-stage...

New rules in China are expected to tighten regulatory oversight of investigator-initiated trials (IITs) while clarifying how sponsors can operate legally across modalities beyond cell and gene...

Tennor Therapeutics priced an $80 million IPO in Hong Kong to fund its antibacterial pipeline, including rifasutenizol (TNP-2198), which the company says could support a targeted combination...

Researchers reported that TREM2-positive macrophages detect candidalysin to trigger an early antifungal immune response during oropharyngeal candidiasis. The work, led by Yunsheng Liang at Central...

Kura Oncology disclosed early combination data showing darlifarnib paired with Bristol Myers Squibb’s Krazati delivered response rates up to 69%, according to the company. The update frames the...

Eli Lilly moved to bulk up its infectious-disease pipeline, agreeing to acquire three companies in deals totaling up to $3.8 billion. The acquisitions target viral and bacterial pathogen R&D and...

The FDA granted accelerated approval to Beqalzi (sonrotoclax) for adults with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy,...

Eli Lilly reported early Phase 1 results for VERV-102, a base-editing gene therapy acquired from Verve Therapeutics, showing a 62% reduction in cholesterol levels at a high dose. The company...

Kura Oncology published early clinical data on darlifarnib (a potential KRAS inhibitor-enabling agent) in combination with Bristol Myers Squibb’s Krazati (adagrasib). The company reported response...

Eurobio Scientific signed an agreement to distribute Canhelp Genomics molecular oncology assays across multiple European markets. The deal covers distribution of the Canhelp-Uca urine-based...

Researchers unveiled a high-speed hyperspectral single-pixel microscopy approach enhanced with a novel line-scan detection system, aiming to improve resolution and throughput for microscopic...

A Nature Communications study reports that transforming growth factor-beta-activated kinase 1 (TAK1) controls acquisition of inflammatory fibroblasts following myocardial infarction in male mice....

Researchers presented an AI system designed to deliver just-in-time, risk-stratified sepsis evaluations in neonatal intensive care units. The approach focuses on earlier detection and decision...

Astellas outlined a multi-year strategy built around cost cuts and revenue growth goals while navigating pressure from major asset exposure, including the Xtandi patent cliff. The company...

A cell therapy study from the University of Edinburgh reported findings aimed at improving outcomes in advanced liver disease driven by cirrhosis and liver failure. The approach uses the patient’s...

The FDA has granted accelerated approval to Beqalzi (sonrotoclax) for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior lines of systemic therapy, including a...

Eli Lilly said early clinical results from its acquired gene-editing therapy, VERV-102, show cholesterol reductions in participants treated at a high dose. Lilly reported a 62% reduction in...